SUBSCRIBE
SUBSCRIBE
News   FDA

Merck KGaA MS Pill Cladribine Rejected by European Medicines Evaluation Agency

September 24, 2010 | 
1 min read
FRANKFURT, Sept 24 (Reuters) - European regulators dealt Merck KGaA (MRCG.DE) a major blow by recommending against its biggest pipeline drug, multiple sclerosis (MS) pill cladribine, adding to a string of setbacks at the company's drugs unit.
FDA Approvals Regulatory Europe
MORE ON THIS TOPIC
Illustration showing large scissors cutting employees in half
Layoffs
Kezar Loses 70% of Staff After FDA Cancels Meeting on Autoimmune Asset
November 10, 2025
 · 
2 min read
 · 
Dan Samorodnitsky
Oct 9, 2019 Milpitas / CA / USA - Johnson & Johnson Vision offices in Silicon Valley; Johnson & Johnson Vision Care, Inc. is part of the American multinational corporation Johnson&Johnson
Approvals
J&J Wins Expansion for Top-Selling Cancer Drug in First for Smoldering Multiple Myeloma
November 7, 2025
 · 
2 min read
 · 
Tristan Manalac
Buying tickets. The hands of the person holding the tickets. Isolated illustration on a yellow background. Template for the design. Trending vector graphics.
Regulatory
Wegovy, Casgevy Among Latest FDA Priority Review Voucher Recipients
November 6, 2025
 · 
3 min read
 · 
Dan Samorodnitsky
Poster sketch image artwork photo collage of body language finger showing gesture symbol thumb down dislike dissatisfied minus no opinion.
FDA
FDA’s Top Cancer Regulator Declined CDER Directorship
November 6, 2025
 · 
2 min read
 · 
Tristan Manalac